Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Common Equity (2016 - 2025)

Tandem Diabetes Care's Common Equity history spans 13 years, with the latest figure at $155.2 million for Q4 2025.

  • For Q4 2025, Common Equity fell 41.02% year-over-year to $155.2 million; the TTM value through Dec 2025 reached $155.2 million, down 41.02%, while the annual FY2025 figure was $155.2 million, 41.02% down from the prior year.
  • Common Equity reached $155.2 million in Q4 2025 per TNDM's latest filing, up from $133.0 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $449.6 million in Q2 2022 to a low of $133.0 million in Q3 2025.
  • Average Common Equity over 5 years is $304.1 million, with a median of $313.8 million recorded in 2023.
  • Peak YoY movement for Common Equity: surged 51.28% in 2021, then tumbled 44.06% in 2025.
  • A 5-year view of Common Equity shows it stood at $433.1 million in 2021, then rose by 1.58% to $439.9 million in 2022, then decreased by 28.71% to $313.6 million in 2023, then dropped by 16.11% to $263.1 million in 2024, then tumbled by 41.02% to $155.2 million in 2025.
  • Per Business Quant, the three most recent readings for TNDM's Common Equity are $155.2 million (Q4 2025), $133.0 million (Q3 2025), and $133.3 million (Q2 2025).